Rationale correction of immunological disorders in patients with gynecologic and oncologic problems during cyclic chemotherapy
Were studied the mechanisms of immunological disorders in 37 women with ovarian cancer in the process of cycle chemotherapy (CT). It is shown that the inclusion of OT imunofan (treatment group) has improved the immunological reactivity, contributed to increasing the total volume of specific therapy. Completeness of cycle chemotherapy in the study group was 94.7%, in the comparison group - 72.2%.